Patients With Chronic Urticaria Have Higher Health‐Care Resource Utilisation: A Danish Nationwide Case–Control Study
Summary Adult and paediatric CU patients had higher HCRU than controls, decreasing after referral to hospital. After omalizumab approval for CSU in 2014, overall HRCU rates decreased among CU patients subsequently.
Authors
- Zarqa Ali (ORCID: https://orcid.org/0000-0003-2411-7177)
- Nadine Chapman‐Rothe
- Cæcilie Bachdal Johansen (ORCID: https://orcid.org/0000-0002-1303-466X)
- Christian Vestergaard (ORCID: https://orcid.org/0000-0001-6485-3158)
- Nana Aviaaja Lippert Rosenø (ORCID: https://orcid.org/0000-0001-5441-3546)
- Tara D. Raftery
- P. Orfanos
- Somaia Naassan (ORCID: https://orcid.org/0009-0009-2612-5307)
- Jacob P. Thyssen
- Alexander Egeberg
- Simon Francis Thomsen
- Jennifer Astrup Sørensen
Institutions
- University of Copenhagen (DK)
- Novartis (Switzerland) (CH)
- Frederiksberg Hospital (DK)
- Aarhus University Hospital (DK)
- Novartis (Ireland) (IE)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1111/cea.70239
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharma